Research publications from Maverex
We share peer-reviewed research publications across oncology, cardiovascular, infectious disease and much more.
Browse or search our latest publications.
The increasing use of population-adjusted indirect comparisons in the NICE Health Technology Assessment (HTA) submission process and the response to these methods
Pooley N, Kisomi M, Embleton N, Langham S. The increasing use of population-adjusted indirect comparisons in the NICE Health Technology Assessment (HTA) submission process and the response to these methods (CO163). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Is evidence on environmental impact included in health technology assessment and does it influence decision-making?
Hubbert L, Embleton N, Wright A, Nicholson L. Is evidence on environmental impact included in health technology assessment and does it influence decision-making? (HTA56). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
Health technology assessment and reimbursement of medical devices in England, France, and Germany
Heptinstall A, Teague R. Health technology assessment and reimbursement of medical devices in England, France, and Germany (HTA243). Poster presented at ISPOR Europe; 6-9th November 2022; Vienna: Austria, 2022
A review of NICE Medtech Innovation Briefings (MIBS) of digital health technologies
Skeldon G, Adkins E, Teague R. POSB291 A review of NICE Medtech Innovation Briefings (MIBS) of digital health technologies. Value Health 2021;24(S2).
Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease
Cook J, Bloom C, Lewis J, Marjenberg Z, Hernando Platz J, Langham S. Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease. J Mark Access Health Policy 2021;9(1):1929757
Patient engagement process in rare disease: how does it differ between countries?
Skeldon G, Adkins E, Ayre S, Langham S, Nicholson L. PRO95 Patient engagement process in rare disease: how does it differ between countries? Value Health 2020;23(Suppl 2):S706
The increasing use and acceptance of alternative statistical approaches to indirect comparison in the NICE HTA submission process
Pooley N, Marjenberg Z, Embleton N, Langham S. The increasing use and acceptance of alternative statistical approaches to indirect comparison in the National Institute of Health and Care Excellence (NICE) health technology assessment (HTA) submission process. Value Health 2019:22(Suppl 3):S814
The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries
Nicholson L, Langham S, Adkins E. The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries. Value Health 2019:22(Suppl 3):S860
Transparency in decision modelling: what, why, who and how?
Sampson CJ, Arnold R, Bryan S, Clarke P, Ekins S, Hatswell A, Hawkins N, Langham S, Marshall D, Sadatsafavi M, Sullivan W, Wilson ECF, Wrightson T. Transparency in decision modelling: what, why, who and how? Pharmacoeconomics 2019;37(11):1355–69
